Jefferson Capital, Inc. is valued at an 8.5 times GAAP price-to-earnings ratio and offers a 5% dividend yield, reflecting market caution due to legal and consumer solvency risks. The company expanded aggressively, deploying $185 million in July and entering the Mexican market, which supports revenue growth and future cash flow visibility. Estimated recoveries increased by 18% to $3.4 billion, providing revenue stability for several years, though profit margins have shrunk due to rising legal and servicing costs. Risks remain from expensive debt, regulatory pressures, shareholder overhang, and reliance on consumer repayments, but these appear largely priced into the current valuation.
Jefferson Capital's valuation and recovery outlook are presented here with Pluang's Financials-sector market data as of Oct 07, 2026 02:11 WIB. Of 85 priced Financials-sector US stocks tradable on Pluang, 53 rose and 31 fell today. Notable movers include CLSK at USD 12.20 with a 1-day change of -2.24% and a typical hold time of 21 days, and HOOD at USD 112.18 with a 1-day change of -1.69% and Pluang order activity showing 61% Sell / 39% Buy. The most notable figure is CLSK's 95% buy order activity on Pluang.
Neogen reported earnings per share of $0.08 and revenue of $222.8 million, both exceeding analyst expectations. The company also announced a strategic partnership with Hinalea Imaging Corp. to develop digital food safety tools. However, Neogen's stoc...
PepsiCo is set to report its Q3 2026 earnings with expectations of $2.29 EPS and $25 billion revenue. The company faces challenges in North America, where organic revenue declined due to pricing pressures and changing consumer preferences. To adapt, ...
Stryker experienced an 8.8% stock drop on September 8, 2026, wiping out over $10 billion in market value due to ongoing manufacturing problems that were thought resolved. Truist Financial lowered its price target from $340 to $310, reflecting concern...
Bank OZK is scheduled to release its Q3 2026 earnings after market close on October 20, providing investors with updated financial results to compare against Citigroup's current Sell rating. The bank's latest balance sheet shows $41.70 billion in tot...
Scotiabank has increased its price target for Pfizer stock from $30.00 to $33.00, suggesting a potential upside of 20.9% from the current trading price of $27.31. Pfizer, a major pharmaceutical company, holds a strong buy rating with a Zacks Rank of ...
